-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGN-193408 SR in Ocular Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGN-193408 SR in Ocular Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGN-193408 SR in Ocular Hypertension Drug Details: AGN-193408 SR is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISB-1442 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISB-1442 in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISB-1442 in Relapsed Multiple Myeloma Drug Details: ISB-1442 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISB-1442 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISB-1442 in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISB-1442 in Refractory Multiple Myeloma Drug Details: ISB-1442 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISB-1302 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISB-1302 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISB-1302 in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISB-2001 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISB-2001 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISB-2001 in Relapsed Multiple Myeloma Drug Details: ISB-2001 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISB-2001 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISB-2001 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISB-2001 in Refractory Multiple Myeloma Drug Details: ISB-2001 is under development...
-
Product Insights
NewT-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024
Empower your strategies with our T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024 report and make more profitable business decisions. T-cell acute lymphoblastic leukemia (T-ALL) is a type of blood cancer that affects T-cell lymphocytes, a type of white blood cell involved in the immune system's function. T-ALL originates from immature T-cells in the bone marrow that fail to mature into normal functioning T-cells. These abnormal cells grow rapidly, crowding out normal blood cells (red blood...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RP-3 in Fibrosarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RP-3 in Fibrosarcoma Drug Details: RP-3 is under development for the treatment of advanced solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISB-1442 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISB-1442 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ISB-1442 in Relapsed Multiple Myeloma Drug Details: ISB-1442 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mometasone Furoate in Rhinosinusitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mometasone Furoate in Rhinosinusitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Mometasone Furoate in Rhinosinusitis Drug Details:LYR-210 is under development for the treatment of...